Stereocontrolled synthesis and biological activity of two diastereoisomers of the potent HIV-1 protease inhibitor saquinavir

Bioorganic and Medicinal Chemistry

Volumn 16, Issue 2, 2008, Pages 902-908

  Righi, Giuliana ^a   Ciambrone, Simona ^a   Bonini, Carlo ^b   Campaner, Pietro ^c  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF BASILICATA   (Italy)

^c UNIVERSITY OF TRIESTE   (Italy)

Author keywords

Epoxy amine; HIV 1 proteasi inhibitor; Peptidomimetic; Saquinavir; Syn hydroxyethylamine isoster

Indexed keywords

2 [2' HYDROXY 4' PHENYL 3'[N (2 QUINOLYLCARBONYL) LEVO ASPARAGINYL]AMINO BUTYL] N TERT BUTYLDECAHYDRO ISOQUINOLINE 3 CARBOXAMIDE; 2 [2' HYDROXY 4' PHENYL 3'[N (2 QUINOLYLCARBONYL) LEVO ASPARAGINYL]AMMINO BUTYL] N TERT BUTYLDECAHYDRO ISOQUINOLINE 3 CARBOXAMIDE; 2,3 EPOXYAMINE DERIVATIVE; AMINE; PROTEINASE INHIBITOR; SAQUINAVIR; UNCLASSIFIED DRUG;

ARTICLE; BIOLOGICAL ACTIVITY; DIASTEREOISOMER; DRUG SYNTHESIS; ENANTIOSELECTIVITY; IC 50; STEREOCHEMISTRY;

COMBINATORIAL CHEMISTRY TECHNIQUES; HIV PROTEASE INHIBITORS; HIV-1; INHIBITORY CONCENTRATION 50; MOLECULAR MIMICRY; MOLECULAR STRUCTURE; PEPTIDES; SAQUINAVIR; STEREOISOMERISM;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 38549119868     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2007.10.020     Document Type: Article

References (40)

1. See review. De Clercq E. J. Med. Chem. 48 (2005) 1297
2. Mitsuya H., Yarchoan R., and Broder S. Science 249 (1990) 1533
3. Leug D., Abbenante G., and Schiltz G. J. Med. Chem. 43 (2000) 305
4. Durunavir (TMC-114) is the newest FDA approved protease inhibitor. Ghosh A.K., Sridhar P.R., Leshchenko S., Hussain A.K., Li J., Kovalevsky A.Y., Walters D.E., Wedekind J.E., Grum-Tokars V., Das D., Koh Y., Maeda K., Gatanaga H., Weber I.T., and Mitsuya H. J. Med. Chem. 49 (2006) 5252
5. Surleraux D.L.N.G., Tahri A., Verschueren W.G., Pille G.M.E., de Kock H.A., Jonckers T.H.M., Peeters A., De Meyer S., Azijn H., Pauwels R., de Bethune M.-P., King N.M., Prabu-Jeyabalan M., Schiffer C.A., and Wigerinck P.B.T.P. J. Med. Chem. 48 (2005) 1813
6. Surleraux D.L.N.G., de Kock H.A., Verschueren W.G., Pille G.M.E., Maes L.J.R., Peeters A., Vendeville S., De Meyer S., Azijn H., Pauwels R., de Bethune M.-P., King N.M., Prabu-Jeyabalan M., Schiffer C.A., and Wigerinck P.B.T.P. J. Med. Chem. 48 (2005) 1965
7. Jaskolski M., Tomasselli A.G., Sawyer D.G., Heinrikson R.L., Schneider J., Kent S.B.H., and Wlodawer A. Biochemistry 30 (1991) 1600
8. Martin J.A., Redshaw S., and Thomas G.J. Prog. Med. Chem. 32 (1995) 239
9. Roberts N.A. Science 248 (1990) 358
10. Synthesis of Saquinavir. Parkes K.E.B. J. Org. Chem. 59 (1994) 3656
11. Fassler A. J. Med. Chem. 39 (1996) 3203
12. Ghosh A.K., Hussian K.A., and Fidanze S. J. Org. Chem. 62 (1997) 6080
13. Condra J.H. Science 267 (1995) 483
14. For a recent report see. Rusconi S., and Viganò O. Therapy 3 (2006) 79
15. Saquinavir: Pdb id 1C6Z.
16. Chen Z., Yan Y., Li Y., Olsen D.B., Schock H.B., Galvin B.B., Dorsey B., and Kuo L.C. Acta Crystallogr. D 56 (2000) 38
17. Krohn A., Redshaw S., Ritchie C.J., Graves B.J., and Hatada M.H. J. Med. Chem. 34 (1991) 11
18. Roberts N.A., et al. Science 248 (1990) 358
19. Righi G., Chionne A., and Bonini C. Eur. J. Org. Chem. (2000) 3127
20. Righi G., Ronconi S., and Bonini C. Eur. J. Org. Chem. (2002) 1573
21. Review. Righi G., and Bonini C. Tetrahedron 58 (2002) 4981
22. Pesenti C., Arnone A., Arosio P., Frigerio M., Meille S.V., Panzeri W., Viani F., and Zanda M. Tetrahedron Lett. 45 (2004) 5125
23. Righi G., D'Achille C., Pescatore G., and Bonini C. Tetrahedron Lett. 44 (2003) 6999
24. Righi G., Bonini C., and Rumboldt G. J. Org. Chem. 61 (1996) 3557
25. Righi G., Ciambrone S., D'Achille C., Leonelli A., and Bonini C. Tetrahedron 62 (2006) 11821
26. Bonini C., Federici C., Righi G., and Rossi L. J. Org. Chem. 60 (1995) 4803
27. Righi G., Bovicelli P., Antonioletti R., and Fazzolari E. Tetrahedron Lett. 41 (2000) 9315
28. Righi, G. Unpublished results.
29. Benedetti F., Berti F., and Norbedo S. J. Org. Chem. 67 (2002) 8635
30. Our approach is remarkably convenient for the preparation of 2, considering that the same (S, S) core is present in Atazanavir, the penultimate FDA approved protease inhibitor. Bold G., Fässler A., Capraro H.-G., Cozens R., Klimkait T., Lazdins J., Mestan J., Poncioni B., Rösel J., Stover D., Tintelnot-Blomley M., Acemoglu F., Beck W., Boss E., Eschbach M., Hürlimann T., Masso E., Roussel S., Ucci-Stoll K., Wyss D., and Lang M. J. Med. Chem. 41 (1998) 3387
31. Nogami H., Kanai M., and Shibasaki M. Chem. Pharm. Bull. 51 (2003) 702
32. Fassler A., Bold G., Capraro H.-G., Cozens R., Mestan J., Poncioni B., Rosel J., Tintelnot-Blomley M., and Lang M. J. Med. Chem. 39 (1996) 3203
33. Tossi A., Bonin I., Antcheva N., Norbedo S., Benedetti F., Miertus S., Nair A.C., Maliar T., Dal Bello F., Palù G., and Romeo D. Eur. J. Biochem. 267 (2000) 1715
34. Tossi A., Benedetti F., Norbedo S., Skrbec D., Berti F., and Romeo D. Bioorg. Med. Chem. 11 (2003) 4719
35. Bonini C., Chiummiento L., De Bonis M., Funicello M., Lupattelli P., Suanno G., Berti F., and Campaner P. Tetrahedron 61 (2005) 6580
36. Darke L.P. Methods Enzymol. 241 (1994) 112
37. Toth M.V., and Marshall G.R. Int. J. Peptide Protein Res. 36 (1990) 544
38. Matayoshi E.D., Wang G.T., Krafft G.A., and Erickson J. Science 247 (1990) 954
39. Bulger P.G., Moloney M.G., and Trippier P.C. Organic Biomol. Chem. 1 (2003) 3726
40. Shum W.P., Chen J., and Cannarsa M.J. Chirality 6 (1994) 681